Bristol Myers Squibb (BMY) announced today that it has agreed to acquire Karuna Therapeutics (KRTX), a biopharmaceutical company focused on psychiatric and neurological disorders, for $330 per share in cash, or $14 billion in total. “There are tremendous opportunities in neuroscience, and Karuna strengthens our position and accelerates the expansion and diversification of our portfolio…